Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 67.44B 59.15B 54.61B 50.47B 95.65B 6,458B 97.57B 657B 255B 3,160B 253B 248B 10,970B P/E 2026 *
17.2x
P/E 2027 * 13.8x
Enterprise Value 59.61B 52.28B 48.27B 44.6B 84.54B 5,707B 86.23B 580B 225B 2,793B 224B 219B 9,696B EV / Sales 2026 *
3.76x
EV / Sales 2027 * 3.24x
Free-Float
72.33%
Yield 2026 *
0.59%
Yield 2027 * 0.67%
1 day+0.89%
1 week+2.03%
Current month+7.06%
1 month+8.34%
3 months-13.06%
6 months-16.19%
Current year-13.52%
1 week 637.72
Extreme 637.715
677.92
1 month 594.9
Extreme 594.9
677.92
Current year 591.52
Extreme 591.52
821.11
1 year 541
Extreme 541
821.11
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 31/12/2000
Chief Executive Officer 73 07/01/1988
Director of Finance/CFO 55 04/02/2024
Director TitleAgeSince
Chairman 73 08/06/2023
Director/Board Member 85 31/05/1991
Director/Board Member 85 31/05/1991
Date Insider Type Main position Quantity % Market Cap.
07-01Sell

Director

-200 0.0002%
04-30Sell

Director

-100 0.0001%
03-31Sell

Director

100 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+0.89%+2.03%+20.81%-5.09% 67.44B
+1.97%-4.16%+48.91%+223.30% 53.98B
-4.15%+36.30%+36.30%+36.30% 41.77B
+0.99%+6.61%-48.49%-52.47% 41.15B
-1.42%-9.09%+47.70%-30.23% 29.58B
+2.05%-6.33%+131.29%-38.39% 29.28B
+0.23%+1.02%+71.78%+90.74% 23.43B
+0.17%+1.17%+4.98%+190.25% 19.11B
+0.91%-0.67%+67.98%+133.30% 16.82B
+19.12%+15.57%+94.01%+413.87% 15.36B
Average +2.07%+2.05%+47.53%+96.16% 33.79B
Weighted average by Cap. +1.09%+1.69%+39.02%+69.27%

Financials

2026 *2027 *
Net sales 15.87B 13.92B 12.85B 11.88B 22.51B 1,520B 22.96B 155B 60.04B 744B 59.61B 58.3B 2,582B 17.55B 15.39B 14.21B 13.13B 24.89B 1,680B 25.39B 171B 66.37B 822B 65.9B 64.46B 2,854B
Net income 4.06B 3.56B 3.29B 3.04B 5.76B 389B 5.88B 39.54B 15.36B 190B 15.25B 14.92B 661B 5.11B 4.48B 4.13B 3.82B 7.24B 489B 7.39B 49.7B 19.31B 239B 19.17B 18.75B 830B
Net Debt -7.83B -6.87B -6.34B -5.86B -11.11B -750B -11.33B -76.26B -29.63B -367B -29.42B -28.77B -1,274B -10.5B -9.21B -8.5B -7.86B -14.89B -1,006B -15.19B -102B -39.72B -492B -39.44B -38.57B -1,708B
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,343
Date Price Change Volume
09/07/26 US$664.51 +0.25% 15,933
08/07/26 US$662.88 -1.97% 746,834
07/07/26 US$676.23 +4.07% 918,937
06/07/26 US$649.81 -0.68% 714,338
02/07/26 US$654.27 +4.73% 1,071,604
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
662.88USD
Average target price
822.48USD
Spread / Average Target
+24.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock